Clinical trial
A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
NCT00061633 is registered in ClinicalTrials.gov with Cumberland Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
- Lead sponsor
- Cumberland Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2003
- Completion date
- January 31, 2004
- Enrollment
- 169 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
abscess, burns, cellulitis, infections, gram-positive bacterial, ulcer, wound infections